ICMR’s annual report 2024 ‘Antimicrobial Resistance Research & Surveillance Network (AMRSN)’, showed that routine drugs like fluoroquinolones, third-generation cephalosporins, carbapenems and piperacillin-tazobactam are rapidly losing effectiveness against bacteria most frequently seen in hospitals.
Related Posts
Cough syrup deaths: SC rejects PIL seeking CBI probe, nationwide drug safety review
Post Views: 24 A bench comprising Chief Justice B R…
Delhi HC sets up expert panel to oversee crowdfunding platform for rare diseases
Post Views: 6 The move comes in a case involving…
Metabolic syndrome in women linked to higher risk of gynaecological cancers: ICMR study
Post Views: 24 Metabolic Syndrome is a cluster of metabolic…